REGENERON PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B |
| Operating income | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B |
| Cash from operations | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B |
| Capital expenditure | $898.4M | $755.9M | $718.6M | $590.1M | $551.9M |
| Free cash flow | $4.1B | $3.7B | $3.9B | $4.4B | $6.5B |
| Share repurchases | $3.4B | $2.6B | $2.2B | $2.1B | $1.6B |
| Total assets | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B |
| Total liabilities | $9.3B | $8.4B | $7.1B | $6.6B | $6.7B |
Shares outstanding 104.8M · Free float 92.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.